2 results about "Ischemic region" patented technology

The application belongs to the field of thrombus-related circulatory disorder disease treatment, and provides application of a Rev-erb alpha agonist in preparation of an anti-platelet aggregation and thrombus-related circulatory disorder medicine. The application finds a new pharmacological effect of the Rev-erb alpha agonist, which can significantly inhibit platelet activation and aggregation, block arterial thrombosis in the whole circulatory system, and increase the level of ischemic area cortical blood supply within 0.5 to 1 hours after stroke. The blood supply increasing approach is recanalization of the infarction area circulatory system, rather than compensation by collateral supply arteries, finally significantly improving motor dysfunction caused by cerebral infarction; and the application provides a new idea and a new drug selection for clinical treatment of coronary heart disease, limb arterial thrombosis, visceral thrombosis, ischemic stroke, disseminated intravascular coagulation, peripheral thrombosis and the like.

This invention provides a biomarker for collateral circulation in CTO patients, MIA3, and its application, belonging to the field of biotechnology. This invention reveals and verifies a significant positive correlation between plasma MIA3 levels and the quality of collateral circulation formation in CTO patients, and its predictive efficacy for good collateral circulation is superior to that of the known key angiogenesis factor VEGFA. This allows MIA3 to serve as a high-value, minimally invasive molecular marker for early, non-invasive identification of a patient's collateral circulation formation potential before interventional surgery, thereby enabling risk stratification and providing an objective basis for individualized treatment decisions (such as whether more aggressive intervention is needed). This invention clarifies that MIA3 is a key link in regulating collateral angiogenesis; by targeting and upregulating MIA3 activity, collateral angiogenesis and maturation in ischemic areas can be precisely promoted, providing a novel non-pharmacological, non-surgical treatment strategy for CTO patients.